A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function

NCT03277755 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Development program of JNJ-4178 was discontinued.

Conditions

Hepatic Impairment

Interventions

DRUG: AL-335 800 mg
DRUG: ODV 25 mg
DRUG: SMV 75 mg

Sponsor

Janssen Research & Development, LLC